MAPT and Alzheimer disease: Further validation and investigation of these DEGs as clinically relevant biomarkers for MCI and AD will ideally be conducted in the future using a much larger dataset (than the current NNI data used in this study), that is also supported by common AD biomarkers such as amyloid and tau.